Supriya Lifesciences, a Mumbai‑based maker of active pharmaceutical ingredients, is betting on big capacity upgrades to push its revenue to about Rs1,000 cr by the fiscal year 2027.
In the September quarter the company rebounded sharply, with revenue up 20% YoY to Rs199.8 cr and EBITDA rising 12% to Rs73 cr. Margins stayed steady at 36% and exports made up 81% of sales. The firm aims for more than 20% annual revenue growth, targeting Rs1,000 cr by FY27, up from roughly Rs706 cr in FY25.
Supriya’s main cash generators are three API molecules:
These three account for more than half of total sales. To lower the risk of relying on a few products, the company is launching new APIs, entering contract development and manufacturing (CDMO) work, and expanding into formulations.
Two major capital projects are under way:
Funding will mainly come from internal cash; the company remains debt‑free with about Rs150 cr in the bank.
Supriya expects margins of 33‑35% going forward, helped by deeper backward integration and larger batch sizes after a 55% increase in reactor capacity. Europe and Latin America stay the biggest markets for now, while North America is set to grow from FY27.
Overall, Supriya Lifesciences is positioning itself for faster growth while keeping profitability stable. Investors should watch the progress of the new plants and the rollout of the diversified product line.
Download the TradeKaizen app to practice F&O trading with real-time market data anytime, anywhere.
Get it on Google PlayConnect with fellow traders, share strategies, and improve your trading skills in our Telegram group.
Join TelegramIndian small‑cap and mid‑cap stocks fell on Jan 12, even after a positive comment from the US ambassador about the India‑US trade relationship. Market Overview The Nifty Smallcap 100 index dropped about 0.8% by mid‑afternoon, while the Nifty Midcap 100 fell around 0.4%. Both indices stayed in the red as broader market sentiment stayed weak. US Ambassador’s Comment US Ambassador Sergio Gor said India is “no partner more essential” for the United States and that the two countries are actively discussing the pending trade deal. He also hinted that President Trump may visit India within the next couple of years, reinforcing the perceived strength of the bilateral relationship. Top Small‑Cap Losers Tejas Networks – fell more than 9% after reporting a Q3 FY26 net loss of ₹196.55 crore, down from a profit a year earlier. Signatureglobal (India) – down nearly 5% after announcing it would miss FY26 pre‑sales guidance. Radico Khaitan, Delhivery, Laurus Labs – each slipped over 4%. NBCC, Natco Pharma, Trident, Zen Technologies – fell around 3%. Top Mid‑Cap Losers Cummins India and Hitachi Energy India – each down about 4%. BHEL, Prestige Estates, Godrej Properties, ITC Hotels – each slipped roughly 3%. Tata Communications, Bharti Hexacom, IDFC First Bank, Kalyan Jewellers, Biocon – each fell around 2%. What It Means for Investors The drop shows that even optimistic diplomatic remarks may not be enough to lift small‑cap and mid‑cap stocks when earnings disappoint or guidance is cut. Investors should watch upcoming earnings reports and any concrete progress on the trade deal before making new bets. Disclaimer Remember, this is my perspective, not a prediction. Do your own research and consider your risk tolerance before acting on any investment ideas.
Indian stock markets closed higher on Jan 12, ending a five‑day losing streak as the Nifty climbed back to around 25,800. Market Snapshot The Sensex rose 302 points (0.36%) to finish at 83,878, while the Nifty gained 107 points (0.42%) to end at 25,790. Mid‑cap and small‑cap indices kept falling, down 0.4% and 0.7% respectively. Sector Highlights Metal stocks jumped about 2%. PSU bank stocks rose 0.7%. FMCG stocks gained 0.6%. Capital goods, pharma, media and realty fell between 0.5% and 1.5%. Top Gainers and Losers Big gainers on the Nifty included Coal India, Trent, Asian Paints, Tata Steel and JSW Steel. Notable losers were Eicher Motors, Infosys, Bajaj Finance, Tata Motors Passenger Vehicles and Bajaj Auto. Individual Stock Moves Lemon Tree Hotels +2% after Warburg Pincus announced a full buy‑out. Signature Global –4.7% as Q3 pre‑sales fell 27%. IREDA +3.7% on a 37% jump in Q3 profit. Shakti Pumps +4% after winning an order worth ₹654 crore. Embassy Developments +5% on a 15% rise in Q3 collections. KP Green +3.6% after securing an ₹819 crore order from BSNL. Tanfac Industries +3% after signing a long‑term supply deal with a Japanese customer. Analyst Views HDFC Securities After a weak start, the Nifty recovered strongly and closed with a solid gain. The chart shows a long bullish candle, suggesting short‑term upside. The next target could be the 26,000–26,100 range. Kotak Securities The market bounced back sharply from early lows. A buy‑on‑dip and sell‑on‑rally approach is recommended for day traders. Key support levels are around 25,650–25,600, while resistance sits near 25,900–25,950. Disclaimer These observations are for informational purposes only and not investment advice. Always do your own research or consult a qualified advisor before making any decisions.
Kernex Microsystems' share price tumbled about 16% on Monday after the company couldn't meet a delivery deadline for a railway order, sending a ripple through other stocks tied to India's Kavach train‑protection system. Missed deadline triggers sell‑off The firm failed to finish an order for Chittaranjan Locomotive Works on time. When it asked for more time, the request was turned down, and the stock opened down 14.6% and fell to a one‑month low of ₹1,011. It’s the fifth straight day the stock has dropped, with a total decline of over 18% in that period. Other Kavach‑linked stocks also slide HBL Engineering fell about 1.9% to ₹861.25. Quadrant Future Tek also closed in the red. These companies, along with CG Power, RailTel and others, are part of the automatic train‑protection (Kavach) system that helps trains brake automatically if the driver misses a signal. What investors should watch The recent rally in Kavach stocks has cooled as investors focus more on actual order execution than just order announcements. A missed deadline can quickly hurt sentiment and trigger broader selling. Remember, this is just an overview, not a prediction. Do your own research or consult a qualified advisor before making any investment decisions.